Key Highlights
- William Fricker, CPA, MBA, appointed as Chief Financial Officer of NeuroTrauma Sciences, bringing over 25 years of financial expertise.
- David Lawrence steps down from CFO role but remains as a consultant and joins the Board of Directors.
- Fricker’s experience includes key roles in pharmaceutical and biotech companies, notably Eleison Pharmaceuticals, NeuroRx, and Immunomedics.
Source: PR Newswire
Notable Quotes
- “NTS is developing neuroprotective compounds in the critically underserved areas of stroke and traumatic brain injury, and I am honored to join the company and leverage my expertise to contribute to its success,” – William Fricker, Chief Financial Officer at NeuroTrauma Sciences
- “Throughout Bill’s significant industry tenure, he has improved financial discipline and supported the finance and operational functions of companies at all stages,” – Carl Long, Chief Executive Officer at NeuroTrauma Sciences
SoH's Take
The appointment of William Fricker as CFO of NeuroTrauma Sciences is a strategic move in fortifying the company’s financial and operational backbone. Fricker’s extensive experience across the pharmaceutical and biotechnology sectors, particularly in companies undergoing significant transitions, positions him ideally for steering NTS’s financial strategy amidst its growth phase. This change, coupled with David Lawrence’s continued involvement as a consultant and board member, ensures continuity and a blend of fresh perspective and historical knowledge. NTS’s focus on developing therapies for CNS injuries, a field with considerable unmet needs, highlights the importance of robust financial leadership to navigate the challenges of bringing pioneering treatments to market.
